collection
MENU ▼
Read by QxMD icon Read
search

Gastroenterology

shared collection
143 papers 100 to 500 followers
https://www.readbyqxmd.com/read/30099106/when-to-resume-direct-oral-anticoagulants-following-gastrointestinal-bleeding
#1
EDITORIAL
Moe H Kyaw, Francis K L Chan
No abstract text is available yet for this article.
August 9, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/30055267/fecal-microbiota-transplantation-current-status-in-treatment-of-gi-and-liver-disease
#2
REVIEW
Byron P Vaughn, Kevin M Rank, Alexander Khoruts
Fecal microbiota transplantation was originally introduced as a method to repair intestinal microbiota following failure of multiple treatments of recurrent Clostridiumdifficile infection with antibiotics. However, it is hypothesized that intestinal dysbiosis may contribute to the pathogenesis of many diseases, especially those involving the gastrointestinal tract. Therefore, fecal microbiota transplantation is increasingly being explored as a potential treatment that aims to optimize microbiota composition and functionality...
July 25, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/30025810/viral-gastroenteritis
#3
REVIEW
Krisztián Bányai, Mary K Estes, Vito Martella, Umesh D Parashar
Enteric viruses, particularly rotaviruses and noroviruses, are a leading cause of gastroenteritis worldwide. Rotaviruses primarily affect young children, accounting for almost 40% of hospital admissions for diarrhoea and 200 000 deaths worldwide, with the majority of deaths occurring in developing countries. Two vaccines against rotavirus were licensed in 2006 and have been implemented in 95 countries as of April, 2018. Data from eight high-income and middle-income countries showed a 49-89% decline in rotavirus-associated hospital admissions and a 17-55% decline in all-cause gastroenteritis-associated hospital admissions among children younger than 5 years, within 2 years of vaccine introduction...
July 14, 2018: Lancet
https://www.readbyqxmd.com/read/30035645/a-safety-review-of-proton-pump-inhibitors-to-treat-acid-related-digestive-diseases
#4
REVIEW
Edoardo Savarino, Elisa Marabotto, Patrizia Zentilin, Manuele Furnari, Giorgia Bodini, Gaia Pellegatta, Greta Lorenzon, Marco Della Coletta, Matteo Ghisa, Claudia Coppo, Carla Marinelli, Vincenzo Savarino
Proton pump inhibitors (PPIs) have become the first choice medical treatment of acid-related disease and, as with any pharmacological agent, they have been reported to be associated with some adverse events mainly linked to their chronic use. The most important postulated harms are represented by serum electrolyte alterations, vitamin B12 and iron deficiency, gastric tumors, enteric infections, spontaneous bacterial peritonitis, pneumonia, ischemic heart attacks, bone fractures, chronic kidney disease, dementia, and Alzheimer disease...
August 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29885299/how-to-maximize-learning-in-a-gastroenterology-fellow-clinic-prepare-to-precept
#5
Navin L Kumar, Molly L Perencevich
No abstract text is available yet for this article.
July 2018: Gastroenterology
https://www.readbyqxmd.com/read/29274867/esophageal-diseases
#6
Rebecca C Fitzgerald, Michael F Vaezi
No abstract text is available yet for this article.
January 2018: Gastroenterology
https://www.readbyqxmd.com/read/29888239/medical-therapy-of-gastroesophageal-reflux-disease-beyond-proton-pump-inhibitors-where-are-we-heading
#7
REVIEW
Herbert Koop
Proton pump inhibitors (PPI) have greatly improved the treatment of gastroesophageal reflux disease. However, recent investigations have revealed that reflux symptoms persist in a substantial number of patients. Therefore, treatment strategies beyond PPI are urgently required. One such strategy may involve more reliable acid suppression, e.g., with new acid inhibitory drugs. Furthermore, the rapid appearance of an acidic compartment in the proximal stomach after a meal, which is largely responsible for postprandial heartburn, requires a specific kind of therapy in addition to PPI which still needs to be established...
April 2018: Visceral Medicine
https://www.readbyqxmd.com/read/29873678/do-recent-reports-about-the-adverse-effects-of-proton-pump-inhibitors-change-providers-prescription-practice
#8
M T Al-Qaisi, A Kahn, M D Crowell, G E Burdick, M F Vela, F C Ramirez
Proton pump inhibitors (PPI) are utilized for a variety of indications, including treatment of gastroesophageal reflux disease, peptic ulcer disease, and prevention of gastrointestinal (GI) bleeding. Several studies have documented an increasing prevalence of inappropriate PPI use. Furthermore, recent media reports have highlighted new research data suggesting a possible association between chronic PPI use and several adverse medical outcomes, leading to frequent patient inquiries about these associations. Thus, providers face the challenge of counseling patients about the balance of risks and benefits related to PPI use...
June 4, 2018: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/29794543/refractory-constipation-what-is-the-clinician-to-do
#9
Kyle Staller
Most clinicians will agree that chronic constipation is characterized by abnormal bowel movement consistency and/or frequency plus or minus evacuation symptoms, but patient perception of constipation varies widely and includes symptoms that may or may not meet official defining criteria. Although intermittent constipation is extremely common, only a small minority of patients seek care for their symptoms. Among these patients, dissatisfaction with the currently available laxative options is not uncommon, and many patients will require specialized care for severe or refractory symptoms-especially those with abdominal pain, irritable bowel syndrome overlap, bloating or distention, and psychological comorbidities...
July 2018: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/29097867/dysphagia-thinking-outside-the-box
#10
REVIEW
Hamish Philpott, Mayur Garg, Dunya Tomic, Smrithya Balasubramanian, Rami Sweis
Dysphagia is a common symptom that is important to recognise and appropriately manage, given that causes include life threatening oesophageal neoplasia, oropharyngeal dysfunction, the risk of aspiration, as well as chronic disabling gastroesophageal reflux (GORD). The predominant causes of dysphagia varies between cohorts depending on the interplay between genetic predisposition and environmental risk factors, and is changing with time. Currently in white Caucasian societies adopting a western lifestyle, obesity is common and thus associated gastroesophageal reflux disease is increasingly diagnosed...
October 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29657605/meta-analysis-of-the-efficacy-and-safety-of-pantoprazole-in-the-treatment-and-symptom-relief-of-patients-with-gastroesophageal-reflux-disease-pan-star
#11
Andrzej Dabrowski, Borut Štabuc, Leonid Lazebnik
Introduction: Proton pump inhibitors therapy success in the treatment of gastroesophageal reflux disease (GERD) is a difficult task because the extent of mucosal damage has no relation with the severity of the symptoms. Aim: To establish the efficacy of pantoprazole treatment in patients with erosive reflux disease (ERD) and in those with non-erosive reflux disease (NERD), by assessing symptom relief and quality of life. Treatment duration and adverse events associated with pantoprazole treatment were analysed...
2018: Przegla̜d Gastroenterologiczny
https://www.readbyqxmd.com/read/29110162/recent-advances-in-the-pharmacological-management-of-gastroesophageal-reflux-disease
#12
REVIEW
Yu-Min Kung, Wen-Hung Hsu, Meng-Chieh Wu, Jiunn-Wei Wang, Chung-Jung Liu, Yu-Chung Su, Chao-Hung Kuo, Fu-Chen Kuo, Deng-Chyang Wu, Yao-Kuang Wang
The management of proton pump inhibitor-refractory GERD (rGERD) is a challenge in clinical practice. Since up to one-third of patients with typical GERD symptoms (heartburn and/or acid regurgitation) are not satisfied with proton pump inhibitor (PPI) therapy, new drug development targeting different pathophysiologies of GERD is imperative. At present, no other drugs serve as a more potent acid suppression agent than PPIs. As an add-on therapy, histamine type-2 receptor antagonists, alginates, prokinetics and transient lower esophageal sphincter relaxation inhibitors have some impact on the subgroups of rGERD, but greater effectiveness and fewer adverse effects for widespread use are required...
December 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28916953/dexlansoprazole-for-heartburn-relief-in-adolescents-with-symptomatic-nonerosive-gastro-esophageal-reflux-disease
#13
MULTICENTER STUDY
Benjamin D Gold, Betsy Pilmer, Jaroslaw Kierkuś, Barbara Hunt, Maria Claudia Perez, David Gremse
BACKGROUND: Proton pump inhibitors are commonly used to treat gastro-esophageal reflux disease (GERD) and nonerosive GERD (NERD) in adolescents and adults. Despite the efficacy of available medications, many patients have persisting symptoms, indicating a need for more effective agents. AIMS: To assess the safety and efficacy of dexlansoprazole dual delayed-release capsules in adolescents for treatment of symptomatic NERD. METHODS: A phase 2, open-label, multicenter study was conducted in adolescents aged 12-17 years...
November 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29691276/asia-pacific-working-group-consensus-on-non-variceal-upper-gastrointestinal-bleeding-an-update-2018
#14
Joseph Jy Sung, Philip Cy Chiu, Francis K L Chan, James Yw Lau, Khean-Lee Goh, Lawrence Hy Ho, Hwoon-Young Jung, Jose D Sollano, Takuji Gotoda, Nageshwar Reddy, Rajvinder Singh, Kentaro Sugano, Kai-Chun Wu, Chun-Yin Wu, David J Bjorkman, Dennis M Jensen, Ernst J Kuipers, Angel Lanas
Non-variceal upper gastrointestinal bleeding remains an important emergency condition, leading to significant morbidity and mortality. As endoscopic therapy is the 'gold standard' of management, treatment of these patients can be considered in three stages: pre-endoscopic treatment, endoscopic haemostasis and post-endoscopic management. Since publication of the Asia-Pacific consensus on non-variceal upper gastrointestinal bleeding (NVUGIB) 7 years ago, there have been significant advancements in the clinical management of patients in all three stages...
October 2018: Gut
https://www.readbyqxmd.com/read/28774844/assessing-old-and-new-diagnostic-tests-for-gastroesophageal-reflux-disease
#15
REVIEW
Michael F Vaezi, Daniel Sifrim
A detailed critique of objective measurements of gastroesophageal reflux disease (GERD) would improve management of patients suspecting of having reflux, leading to rational selection of treatment and better outcomes. Many diagnostic tests for GERD have been developed over the past decades. We analyze their development, positive- and negative-predictive values, and ability to predict response to treatment. These features are important for development of medical, surgical, and endoscopic therapies for GERD. We discuss the value of available diagnostic tests and review their role in management of patients with persistent reflux symptoms despite adequate medical or surgical treatment...
January 2018: Gastroenterology
https://www.readbyqxmd.com/read/29681623/lack-of-improvement-of-impaired-chemical-clearance-characterizes-ppi-refractory-reflux-related-heartburn
#16
Marzio Frazzoni, Leonardo Frazzoni, Salvatore Tolone, Nicola De Bortoli, Vincenzo Savarino, Edoardo Savarino
OBJECTIVE: Heartburn is the most specific symptom of reflux disease and is highly responsive to proton pump inhibitor (PPI) therapy. Some patients do not respond to PPIs, but mechanisms of refractoriness have not yet been fully elucidated. Impedance-pH monitoring, allowing comprehensive on-therapy assessment of reflux, represents a valuable test to investigate PPI refractoriness. METHODS: Prospective multicenter study comparing endoscopy-negative patients with PPI-refractory and PPI-responsive heartburn...
May 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29668562/the-association-between-proton-pump-inhibitor-use-with-acute-kidney-injury-and-chronic-kidney-disease
#17
Faisal Kamal, Muhammad A Khan, Miklos Z Molnar, Colin W Howden
Proton pump inhibitors (PPIs) are among the most commonly prescribed medicines and are the mainstay of treatment for gastroesophageal reflux disease. Recently, there has been an increase in the use of these medicines for unclear and inappropriate indications. Although generally well tolerated and considered to be safe, several observational studies have linked PPI use with a variety of conditions such as pneumonia, Clostridium difficile infection, fractures, hypomagnesemia, and dementia. The well-established association between PPIs and acute interstitial nephritis has raised questions about whether they may also cause acute kidney injury and chronic kidney disease...
July 2018: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/29161458/proton-pump-inhibitors-for-functional-dyspepsia
#18
REVIEW
Maria Ines Pinto-Sanchez, Yuhong Yuan, Ahmed Hassan, Premysl Bercik, Paul Moayyedi
BACKGROUND: Functional dyspepsia (FD or non-ulcer dyspepsia) is defined as continuous or frequently recurring epigastric pain or discomfort for which no organic cause can be found. Acid suppressive therapy, including proton pump inhibitors (PPIs), has been proposed as a therapeutic option in FD, but its efficacy remains controversial. While PPIs are generally considered safe and well tolerated, they have been associated with adverse events, especially in the long term. For this reason, decisions on whether to initiate or continue PPI therapy should be made based on an appropriate clinical indication...
November 21, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29653941/guidelines-for-the-investigation-of-chronic-diarrhoea-in-adults-british-society-of-gastroenterology-3rd-edition
#19
Ramesh P Arasaradnam, Steven Brown, Alastair Forbes, Mark R Fox, Pali Hungin, Lawrence Kelman, Giles Major, Michelle O'Connor, Dave S Sanders, Rakesh Sinha, Stephen Charles Smith, Paul Thomas, Julian R F Walters
Chronic diarrhoea is a common problem, hence clear guidance on investigations is required. This is an updated guideline from 2003 for the investigations of chronic diarrhoea commissioned by the Clinical Services and Standards Committee of the British Society of Gastroenterology (BSG). This document has undergone significant revision in content through input by 13 members of the Guideline Development Group (GDG) representing various institutions. The GRADE system was used to appraise the quality of evidence and grading of recommendations...
August 2018: Gut
https://www.readbyqxmd.com/read/29601902/rethinking-what-we-know-about-hemorrhoids
#20
REVIEW
Robert S Sandler, Anne F Peery
Although hemorrhoids are responsible for considerable economic cost and personal suffering, they have received surprisingly little research attention. In the United States, hemorrhoids are the third most common outpatient gastrointestinal diagnosis with nearly 4 million office and emergency department visits annually. The etiology of hemorrhoids is speculative. A low-fiber diet and constipation have historically been thought to increase the risk for hemorrhoids, but not proven. Symptoms commonly attributed to hemorrhoids include bleeding, pain, pruritus, fecal seepage, prolapse, and mucus discharge...
March 27, 2018: Clinical Gastroenterology and Hepatology
label_collection
label_collection
4746
1
2
2018-04-11 01:57:01
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"